Cybin Announces Completion of Underwritten Public Offering of Units
On November 14, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic treatment options, announced the completion of its underwritten public offering of units. In connection with the offering, Cybin issued an aggregate of 66,666,667 units at a price of US$0.45 per unit for aggregate gross proceeds of US$30 million.
Each unit consisted of one common share and one common share purchase warrant of Cybin. A.G.P./Alliance Global Partners acted as sole book-running manager of the offering.
Cybin intends to use the net proceeds of the offering for the progression of Cybin's CYB003 and deuterated DMT programs, and for general corporate and working capital purposes.
Aird & Berlis represented Cybin with a team led by Sherri Altshuler and including Danny Kharazmi, Sean Green, Meredith McCann and Karlie Nordstrom.
-
BioFull bio
Sherri earns the trust of her clients by adeptly managing complex and time-sensitive corporate finance transactions and by providing relevant, busines...
-
BioFull bio
Danny thrives on finding effective and creative solutions to help clients navigate through highly-regulated industries.
-
BioFull bio
When it comes to complex capital markets transactions, Sean provides clients with the support they need to navigate corporate laws and achieve their b...
-
BioFull bio
When it comes to complex capital markets transactions or navigating regulatory requirements, Meredith’s primary focus is on her clients’ i...
-
BioFull bio
Karlie thrives on the challenging and dynamic nature of securities law.
